GENEVA–(BUSINESS WIRE)– #ASD–STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for a first application of STALICLA’s precision medicine discovery platform in autism spectrum disorders. The goal of this phase 1b, double-blind, placebo-controlled study was to evaluate the s
